Fundz

SCYNEXIS

Jersey City, New Jersey, United States · Biotechnology, Health Care

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.

Key facts

Headquarters
Jersey City, New Jersey, United States
Employees
61
Industries
Biotechnology, Health Care
Status
Public (SCYX)
Website
www.scynexis.com
LinkedIn
Company page

Recent activity at SCYNEXIS

  • : SEC 8-K (1.01): On September 25, 2026, SCYNEXIS, Inc. entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of SCY-247, a second-generation fungerp antifungal candidate. The BARDA Contract stipulates potential non-dilutive funding of up to $214 million, with an initial base period starting in September 2026 that allocates approximately $18.5 million for advancing SCY-247 into a Phase 2 study in patients with invasive candidiasis. Further funding is contingent on BARDA exercising up to six options, potentially extending the contract for an additional ten years, which underscores the strategic partnership's significance in bolstering antifungal treatment efforts.
  • : SEC 8-K (5.02): On September 18, 2026, SCYNEXIS, Inc. appointed Steven K. Burke, M.D., to its Board of Directors. His appointment is effective immediately and will last until the 2027 Annual Meeting of Stockholders. Dr. Burke has also been assigned to the Nominating and Corporate Governance Committee. As compensation, he will receive an annual retainer of $45,000 and an additional $5,000 for committee service, alongside an option grant to purchase 5,750 shares of the company's common stock at an exercise price of $4.46. This change in board composition is expected to enhance governance and oversight for the company.
  • : SCYNEXIS Appoints Sanjay Subramanian as New Chief Financial Officer
  • : SEC 8-K (5.02): On September 9, 2026, Ivor Macleod, the Chief Financial Officer of SCYNEXIS, Inc., notified the company of his intent to retire, effective the same day. Mr. Macleod will assist with a smooth transition until October 9, 2026, after which he will cease employment with SCYNEXIS. Furthermore, the company announced the appointment of Sanjay Subramanian as the new Chief Financial Officer, effective September 10, 2026. This transition in leadership may impact the company's financial strategies and operations moving forward.
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01): On May 19, 2026, the Board of Directors of SCYNEXIS, Inc. approved a Certificate of Amendment for a one-for-eight (1:8) reverse stock split of its common stock, which will be effective on May 29, 2026. The amendment reduces the total number of authorized shares from 150,000,000 to 18,750,000, with a corresponding adjustment to stock options and warrants. The company will not issue fractional shares; instead, stockholders entitled to fractions will receive cash payments. The split-adjusted common stock will begin trading on the Nasdaq Capital Market on June 1, 2026, under the ticker symbol 'SCYX'.
  • : SEC 8-K (5.02):
  • : SEC 8-K (7.01): On March 31, 2026, SCYNEXIS, Inc. conducted a conference call to discuss its asset acquisition transaction and provide a corporate update. The presentation used during the call, which is attached as Exhibit 99.1, offers summary information regarding the Company’s operations and strategic developments. This disclosure is part of Regulation FD to ensure transparency with investors about significant corporate activities. The information shared during this call is not admitted as material but aims to supplement earlier filings with the SEC, which reflect the current status of the Company’s asset acquisition initiatives.
  • : SEC 8-K (1.01): On March 30, 2026, the Company entered into a Securities Purchase Agreement with institutional and accredited investors for a Private Placement. The agreement involves the issuance of 34,750,000 shares of common stock and additional warrants to purchase up to 43,500,000 shares. The shares and accompanying warrants were sold at a combined price of $0.92 per share. Dr. David Angulo, the Company's President and CEO, acquired 108,695 shares in this deal. This financing arrangement includes terms for stockholder approval within 90 days for an increase in authorized shares, reflecting a strategic move to bolster the company's capital and support its clinical study development efforts.
  • : SEC 8-K (1.01): On March 30, 2026, SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire all rights and interests related to Poxel’s direct AMP kinase activator research and development program assets. The transaction includes a one-time payment of $8,000,000 and potential milestone payments totaling up to $188,000,000 based on specific development and commercial achievements. Key milestones include significant payments associated with clinical trials and commercial sales of related products. The agreement also grants SCYNEXIS exclusive rights under certain licensed intellectual property and contains standard indemnification provisions, governed by New York law. This agreement marks a strategic expansion for SCYNEXIS into innovative therapeutic solutions.

Leadership

  • James Davis, Director Program Management
  • Ivor Macleod, Principal
  • Sanjay Subramanian, Chief Financial Officer
  • Rossana Ferrara, VP, Business Development & Alliance Management

Verified email and direct lines for SCYNEXIS’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

SCYNEXIS files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

SCYNEXIS in the news

Companies similar to SCYNEXIS

About SCYNEXIS: questions and answers

What does SCYNEXIS do?

SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.

Where is SCYNEXIS headquartered?

SCYNEXIS is headquartered in Jersey City, New Jersey, United States.

How many employees does SCYNEXIS have?

SCYNEXIS has about 61 employees.

What is the latest news on SCYNEXIS?

On Sep 25, 2026, SEC 8-K (1.01): On September 25, 2026, SCYNEXIS, Inc. entered into a material definitive agreement with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of SCY-247, a second-generation fungerp antifungal candidate. The BARDA Contract stipulates potential

Is SCYNEXIS a public company?

Yes. SCYNEXIS is publicly traded under the ticker SCYX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches SCYNEXIS across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.